Biodegradable nanoparticles - From sustained release formulations to improved site specific drug delivery

Journal of Controlled Release

Volumn 39, Issue 2-3, 1996, Pages 339-350

  Leroux, Jean Christophe ^a   Allémann, Eric ^a   De Jaeghere, Fanny ^a   Doelker, Eric ^a   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Drug targeting; Nanoparticle; Opsonization; Photodymanic therapy; Poly(lactic acid); Sustained release

Indexed keywords

HEXAFLUORO ZINC PHTHALOCYANINE; NANOPARTICLE; NEUROLEPTIC AGENT; PHOTOSENSITIZING AGENT; POLYGLACTIN; SAVOXEPINE; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL CELL; ANIMAL TISSUE; BIODEGRADATION; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SPECIFICITY; HUMAN; HUMAN CELL; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; OPSONIZATION; PHARMACEUTICS; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; RAT; SUSTAINED RELEASE PREPARATION;

EID: 0343026322     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/0168-3659(95)00164-6     Document Type: Conference Paper

References (52)

1. E. Allémann, R. Gurny and E. Doelker, Drug loaded nanoparticles - Preparation methods and drug targeting issues, Eur. J. Pharm. Biopharm. 39 (1993) 173-191.
2. P. Couvreur and C. Vauthier, Polyalkylcyanoacrylate nanoparticles as drug carrier: present state and perspectives, J. Control. Release 17 (1991) 187-198.
3. P. Couvreur, L. Grislain, V. Lenaerts, F. Brasseur, P. Guiot and A. Biernacki, Biodegradable polymeric nanoparticles as drug carrier for antitumor agents, in: P. Guiot and P. Couvreur (Eds), Polymeric Nanoparticles and Microspheres, CRC Press, Boca Raton, FL, 1986, pp. 27-93.
4. N. Chiannilkulchai, N. Ammoury, B. Caillou, J.P. Devissaguet and P. Couvreur, Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticuloma M 5076 metastasis-bearing mice, Cancer Chemother. Pharmacol. 26 (1990) 122-126.
5. N. Chiannilkulchai, Z. Driouich, J.P. Benoit, A.L. Parodi and P. Couvreur, Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. Sel. Cancer Ther. 5 (1989) 1-11.
6. P. Couvreur, E. Fattal and A. Andremont, Liposomes and nanoparticles in the treatment of intracellular bacterial infections, Pharm. Res. 8 (1991) 1079-1086.
7. J.C. Leroux, E. Doelker and R. Gurny, The use of drug-loaded nanoparticles in cancer chemotherapy, in: S. Benita. (Ed.), Microencapsulation Methods and Industrial Applications, Marcel Dekker, New York, 1996, in press.
8. R. Gurny, H. Ibrahim and P. Buri, The development and use of in situ formed gels, triggered by pH, in: P. Edman. (Ed.), Biopharmaceutics of Ocular Drug Delivery, CRC Press, Boca Raton, FL, 1993, pp. 81-90.
9. L. Illum and S.S. Davis, Effect of the nonionic surfactant poloxamer 338 on the fate and deposition of polystyrene microspheres following intravenous administration, J. Pharm. Sci. 72 (1983) 1086-1089.
10. 14C-poly(methyl methacrylate) nanoparticles, J. Microencapsul. 9 (1992) 19-28.
11. S.J. Douglas, S.S. Davis and L. Illum, Biodistribution of poly(butyl 2-cyanoacrylate) nanoparticles in rabbits, Int. J. Pharm. 34 (1986) 145-152.
12. A. Rolland, Pharmacokinetics and tissue distribution of doxorubicin-loaded polymethacrylic nanoparticles in rabbits, Int. J. Pharm. 42 (1988) 145-154.
13. T.M. Allen and A. Chonn, Large unilamellar liposomes with low uptake into the reticuloendothelial system, FEBS Lett. 223 (1987) 42-46.
14. M.C. Woodle, Surface-modified liposomes: assessment and characterization for increased stability and prolonged blood circulation, Chem. Phys. Lipids 64 (1993) 249-262.
15. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, C. Redemann and F.J. Martin, Sterically stabilized liposomes: improvement in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad. Sci. USA 88 (1991) 11460-11464.
16. S. Stolnik, S.E. Dunn, M.C. Garnett, M.C. Davies, A.G.A. Coombes, D.C. Taylor, M.P. Irving, S.C. Purkiss, T.F. Tadros, S.S. Davis and L. Illum, Surface modification of poly(lactide-co-glycolide) nanospheres by biodegradable poly(lactide)-poly(ethylene glycol) copolymers, Pharm. Res. 11 (1994) 1800-1808.
17. J.C. Leroux, P. Gravel, L. Balant, B. Volet, B.M. Anner, E. Allémann, E. Doelker and R. Gurny. Internalization of poly(DL-lactic acid) nanoparticles by isolated human leukocytes and analysis of plasma proteins adsorbed onto the particles, J. Biomed. Mater. Res. 28 (1994) 471-481.
18. E. Allémann, N. Brasseur, O. Benrezzak, J. Rousseau, S.V. Kudrevich, J.C. Leroux, R. Gurny and J.E. Van Lier, PEG-coated poly(lactic acid) nanoparticles for the delivery of hexadecafluoro zinc phthalocyanine to EMT-6 mouse mammary tumours, J. Pharm. Pharmacol. 47 (1995) 382-387.
19. E. Allémann, R. Gurny and E. Doelker, Preparation of aqueous polymeric nanodispersions by a reversible salting-out process, influence of process parameters on particle size, Int. J. Pharm. 87 (1992) 247-253.
20. E. Allémann, E. Doelker and R. Gurny, Drug loaded poly(lactic acid) nanoparticles produced by a reversible salting-out process: purification of an injectable dosage form, Eur. J. Pharm. Biopharm. 39 (1993) 13-18.
21. E. Allémann, J.C. Leroux, R. Gurny and E. Doelker, In vitro sustained release properties of drug loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure, Pharm. Res. 10 (1993) 1732-1737.
22. 14C-savoxepine loaded poly(DL-lactic acid) nanospheres to rats, J. Control. Release 29 (1994) 97-104.
23. S.C. Rockwell, R.F. Kallman and L.P. Fajardo, Characteristics of a serially transplanted mouse mammary tumour and its tissue-culture-adapted derivative, J. Natl. Cancer Inst. 49 (1972) 735-749.
24. R. Gurny, N.A. Peppas, D.D. Harrington and G.S. Banker, Development of biodegradable and injectable latices for controlled release of potent drugs, Drug. Dev. Ind. Pharm. 7 (1981) 1-25.
25. P. Couvreur, V. Lenaerts, B. Kante, M. Roland and P. Speiser, Oral and parenteral administration of insulin associated to hydrolysable nanoparticles, Acta Pharm. Technol. 26 (1980) 220-222.
26. B. Hubert, J. Atkinson, M. Guerret, M. Hoffman, J.P. Devissaguet and P. Maincent, The preparation and acute antihypertensive effects of a nanocapsular form of darodipine, a dihydropyridine calcium entry blocker, Pharm. Res. 8 (1991) 734-738.
27. B.G. Müller and T. Kissel, Camouflage nanospheres: a new approach to bypassing phagocytic blood clearance by surface modified particulate carriers, Pharm. Pharmacol. Lett. 3 (1993) 67-70.
28. R. Gref, Y. Minamitake, M.T. Peracchia, V.S. Trubetskoy, V. Torchilin and R. Langer, Biodegradable long circulating polymeric nanospheres, Science 263 (1994) 1600-1603.
29. S.E. Dunn, A. Brindley, S.S. Davis, M.C. Davies and L. Illum, Polystyrene-poly (ethylene glycol) (PS-PEG2000) particles as model systems for site specific drug delivery. 2. The effect of PEG surface density on the in vitro cell interaction and in vivo biodistribution, Pharm. Res. 11 (1994) 1016-1022.
30. T.M. Allen, The use of glycolipids and hydrophilic polymers in avoiding rapid uptake of liposomes by the mononuclear phagocyte systems, Adv. Drug Deliv. Rev. 13 (1994) 285-309.
31. D. Needham, T.J. McIntosh and D.D. Lasic, Repulsive interactions and mechanical stability of polymer-grafted lipid membranes, Biochim. Biophys. Acta 1108 (1992) 40-48.
32. V.P. Torchilin, V.G. Omelyanenko, M.I. Papisov, A.A. Bogdanov. V.S. Trubetskoy, J.N. Herron and C.A. Gentry, Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity, Biochim. Biophys. Acta 1195 (1994) 11-20.
33. G. Blume and G. Cevc, Molecular mechanism of the lipid vesicle longevity in vivo, Biochim. Biophys. Acta 1146 (1993) 157-168.
34. H.M. Patel. Serum opsonins and liposomes: their interaction and opsonophagocytosis, Crit. Rev. Ther. Drug Carrier Syst. 9 (1992) 39-90.
35. R.H. Müller, K.H. Wallis, S.D. Tröster and J. Kreuter, In vitro characterization of poly(methyl-metacrylate) nanoparticles and correlation to their in vivo fate, J. Control. Release 20 (1992) 237-246.
36. T. Blunk, D.F. Hochstrasser, J.C. Sanchez, B.W. Müller and R.H. Müller, Colloidal carriers for intravenous drug targeting: plasma protein adsorption patterns on surface modified latex particles evaluated by two-dimensional polyacrylamide gel electrophoresis, Electrophoresis 14 (1993) 1382-1387.
37. P. Artusson and I. Sjöholm, Effect of opsonins on the macrophage uptake of polyacrylstarch microparticles, Int. J. Pharm. 32 (1986) 165-170.
38. M.E. Norman, P. Williams and L. Illum, Influence of block copolymers on the adsorption of plasma proteins to microspheres, Biomaterials 14 (1993) 193-202.
39. S.M. Moghimi, I.S. Muir, L. Illum, S.S. Davis and V. Kolb-Bachofen, Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum, Biochim. Biophys. Acta 1179 (1993) 157-165.
40. T. Blunk, D.F. Hochstrasser, B.W. Müller and R.H. Müller, 2-D PAGE analysis of plasma protein adsorption on colloidal drug carriers, Proc. Int. Symp. Control. Release Bioact. Mater. 20 (1993) 284-285.
41. T. Blunk, D.F. Hochstrasser, B.W. Müller and R.H. Müller, Differential adsorption: effect of plasma protein adsorption patterns on organ distribution of colloidal drug carriers, Proc. Int. Symp. Control. Release Bioact. Mater. 20 (1993) 256-257.
42. T. Blunk, T.K. Bock. D.F. Hochstrasser, J.C. Sanchez, B.W. Müller and R.H. Müller, Plasma protein adsorption patterns on fat emulsions compared to modified latex particles, Proc. Int. Symp. Control. Release Bioact. Mater. 21 (1994) 503-504.
43. R.H. Müller, T. Blunk, M. Lück, D.F. Hochstrasser, J.C. Sanchez and B.W. Müller, Protein adsorption on a range of surface-modified polystyrene particles-evaluation by HR two-dimensional polyacrylamide gel electrophoresis, Eur. J. Pharm. Sci. 2 (1994) 92.
44. T. Blunk, M. Lück, D.F. Hochstrasser, A. Sanchez, B.W. Müller and R.H. Müller, Kinetics of protein adsorption on model particles for drug targeting, Eur. J. Pharm. Sci. 2 (1994) 192.
45. D. Labarre, M. Vittaz, G. Spenlehauer, D. Bazile and M. Veillard, Complement activation by nanoparticulate carriers, Proc. Int. Symp. Control. Release Bioact. Mater. 21 (1994) 91-92.
46. 14C)-poly(lactic acid) nanoparticles coated with albumin after parenteral administration to rats, Biomaterials 13 (1992) 1093-1102.
47. T. Verrecchia, G. Spenlehauer, D.V. Bazile and M. Veillard, Poly(lactic acid)-poly(ethylene glycol) (PLAPEG): a new copolymer for injectable drug carriers, Tech. Bull. Gattefossé 87 (1994) 55-62.
48. D.C. Litzinger, A.M.J. Buiting, N. Van Rooijen and L. Huang, Effect of liposome size on the circulation time and intraorgan distribution of amphipatic poly(ethylene glycol)-containing liposomes, Biochim. Biophys. Acta 1190 (1994) 99-107.
49. S.S. Davis, L. Illum, S.M. Moghimi, M.C. Davies, C.J.H. Porter, I.S. Muir, A. Brindley, N.M. Christy, M.E. Norman, P. Williams and S.E. Dunn, Microspheres for targeting drugs to specific body sites, J. Control. Release 24 (1993) 157-163.
50. G. Poste, Drug targeting in cancer therapy, in: G. Gregoriadis, G. Poste, J. Senior and A. Trouet (Eds), Receptor-mediated Targeting of Drugs, Plenum Press, New York, 1984, pp. 427-475.
51. A. Klibanov, K. Maruyama, A.M. Beckerleg, V. Torchilin and L. Huang, Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposomes binding to target, Biochim. Biophys. Acta 1062 (1991) 142-148.
52. G. Blume, G. Cevc, M.D.J.A. Crommelin, I.A.J.M. Bakker-Wondenberg, C. Kluft and G. Storm, Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times, Biochim. Biophys. Acta 1149 (1993) 180-184.